What is anhedonia

Anhedonia is the decreased ability to experience pleasure from positive stimuli such as social interaction, eating, or sex or a degradation in the recollection of pleasure previously experienced ¹. Anhedonia is a facet of the broad personality trait domain ¹. Anhedonia is a lack of enjoyment from, engagement in or energy for life’s experiences; deficits in the capacity to feel pleasure or take interest in things ¹. This state is caused by a sheer lack of joy during extreme bouts of depression. One of the factors that has been linked to anhedonia is stress. Anhedonia has been the most extensively studied in major depression ², but, as it also constitutes one important negative symptom of schizophrenia, much literature has also been devoted to anhedonia in psychosis ³. Anhedonia has in fact been studied in a large range of neuropsychiatrie disorders, including substance use disorder ⁴, Parkinson’s disease ⁵, overeating ⁶ and various risky behaviors ⁷.

Notably, anhedonic patients with affective disorders have a poorer treatment prognosis than their non-anhedonic counterparts ⁸. Accumulating evidence suggests that standard treatments for depression do little to alleviate anhedonia ⁹ and may even cause reward and emotional blunting ¹⁰, sexual anhedonia ¹¹ and anorgasmia ¹². Furthermore, the presence of anhedonia in a major depressive episode is a predictor of proximal suicide completion ¹³. Critically, no US Food and Drug Administration-approved treatment currently exists specifically for anhedonia.

Social anhedonia is defined as an affective construct (less pleasure derived from social encounters) ¹⁴, little is known about the emotional responsivity and expressivity of individuals with high levels of social anhedonia.

Anhedonia is a prominent symptom in neuropsychiatric disorders, most markedly in major depressive disorder and schizophrenia ¹⁵. Based on the latest studies, anhedonia is a multidimensional construct and should not simply be considered as ‘loss of an ability to experience pleasure’ ¹⁵. Deficits in other reward processes, such as valuation, motivation and decision-making, may lead to behaviors that can be interpreted as anhedonia ¹⁶. Hence, distinguishing the deficits in different cognitive subcomponents of anhedonia is essential to identify its neurobiological substrates. Some investigators have suggested dichotomizing anhedonia into ‘consummatory anhedonia’ (the hedonic response to rewards) and ‘anticipatory anhedonia’ (diminished motivation to pursue rewards) ¹⁷. Others hold that studies should move away from conceptualization of anhedonia as a steady-state, mood-like phenomena, and instead focus on the reward-related motivational/decisional-making aspect ¹⁸. Still others propose to bridge the gap between preclinical and clinical studies by isolating the neural substrates of various processes, such as sensing a pleasant stimulus or anticipating expected rewards, computing value and associated costs, determining effort required, deciding to obtain the reward, increasing motivation and performing the action ¹⁶. Changing research strategies and models demand more complicated and elaborate experimental designs to investigate the underlying neural bases of anhedonia.

Depressed patients must display one of two core symptoms of depression: anhedonia or feelings of sadness ¹⁹. Studies have shown that anhedonia and reduced reward learning ²⁰ predict a poorer prognosis ²¹, with a higher prevalence of treatment failure among anhedonic patients ⁸. The number of depressed patients with anhedonia suggests that aberrant reward processing, perhaps due to changes in reward circuitry, is a core mechanism underlying depression pathophysiology ²². Recent neuroimaging studies in depressed patients show reduced activation of the reward circuitry in depression, specifically the nucleus accumbens and anterior cingulate cortex ²³. Several studies have shown that deep brain stimulation of either the nucleus accumbens or anterior cingulate cortex ameliorates anhedonia in treatment-refractory depression ²⁴. A greater understanding of the cellular mechanisms within brain reward circuitry is needed to provide insights into the anhedonic state and reveal new therapeutic targets.

In depression research, anhedonic depression has been suggested as a specific phenotype ²⁵. Further, in the Research Domain Criteria framework, anhedonia has been suggested as a core construct in the cross-diagnostic study of psychopathology ²⁶. Hence, anhedonia might constitute a crossover phenotype between the affective and the trauma-related spectrum. The above mentioned findings motivate further research into symptoms bridging post-traumatic stress and depression such as anhedonia ²⁷.

Anhedonia has been linked to reward functioning and deficits therein ²⁸. Reward functioning is the ability to feel pleasure when consuming or collecting stimuli of positive valence. Further, it implies being motivated for obtaining such stimuli and promoting behaviour that produces them. As such, reward is pivotal for driving many human behaviours. Following this, different phases of reward functioning may be defined as distinct behaviors ²⁹. Reward wanting is the anticipatory motivation towards obtaining the stimulus, whereas reward consumption is linked to the pleasure felt by obtaining the stimulus. Reward learning is the ability to increase the amount of obtained stimuli by predicting and performing reward-producing behaviors.

Anhedonia is a common symptom following exposure to traumatic stress and a feature of the post-traumatic stress disorder (PTSD) diagnosis ³⁰. In recent factor analytic studies of PTSD, anhedonia has been found to constitute an independent symptom cluster of PTSD ³¹. Specifically, in a 7-factor model of PTSD, anhedonia consists of three symptoms, namely loss of interest, detachment and restricted range of affect ³¹. This anhedonia symptom cluster has been shown to be strongly associated with current depression, reduced mental functioning and quality of life as well as increased suicidal ideation ³². As such, anhedonia might not only suggest severe PTSD, but constitute a comorbidity link between PTSD and depression and be a useful predictor of mental dysfunction and reduced quality of life in trauma survivors ³⁰.

Anhedonia is also common in addictive disorders, including cocaine, but also alcohol, opiate, amphetamine, and cannabis disorders ³³. Across substances of abuse, the presence of anhedonia correlates with withdrawal symptom severity, craving, and likelihood of relapse, suggesting anhedonia may predict a more difficult course of addiction and worse treatment outcomes ³³. Several studies support the hypothesis that anhedonia is a poor prognostic sign in substance use disorders. For example, lifetime presence of anhedonia significantly predicts continued smoking during smoking cessation treatment, even after adjusting for the potential impact of co-occurring depressed mood ³⁴. Another study found that opiate dependent individuals who were less aroused by pleasant, non-drug related pictures were more likely to continue using heroin during treatment ³⁵.

Anhedonia, a lowered ability to experience pleasure, has been found to be associated with suicidal ideation or suicide attempts in various samples of university students, subjects with depressive spectrum disorders, depressed adolescents, and psychiatric patients ³⁶. The search for a relationship between anhedonia and suicide has, however, provided mixed results ³⁷. This discrepancy within literature can be explained by, for instance, taking into account the severity and the type of anhedonia. When anhedonia is severe and constitutes an acute dimension, as is the case in depressive disorders, anhedonia is associated with high risk of suicide ³⁸. When anhedonia is chronic, as is the case in in non-psychiatric subjects or in stable negative schizophrenia subjects, anhedonia is associated with a low level of suicide compared to the studies’ control groups ³⁹. Recently, anticipatory and consummatory anhedonia have been clearly defined as two separate entities ⁴⁰. However, this distinction has not yet been explored in relation to suicidality. Still, several authors ⁴¹ previously suggested that recent change in anhedonia and particularly in its social component may be especially predictive of suicidal ideation. Two recent studies have explored this hypothesis.

In the first study, anhedonia was evaluated twice among 1529 psychiatric patients ⁴¹, once on admission and once 6 weeks later. Anhedonia was rated using a subscale from the Beck Depression Inventory (BDI-II) which comprised four items (loss of interest, loss of pleasure, loss of interest in sex and loss of energy). Suicidal ideation was rated using the “Suicidal thoughts and wishes” item of the BDI-II. These were separated from a subscale derived from the BDI-II which measured cognitive and affective symptoms of depression. Anhedonia was associated with suicidal ideation at baseline and termination even when the cognitive/affective dimension of depression was controlled for. However, symptom-level analyses showed that loss of interest and loss of pleasure were associated with a higher level of suicidal ideation at baseline and that loss of interest was associated with a higher level of suicidal ideation at termination. Winer et al. ⁴¹ suggest that recent change of anhedonia, as rated by the anhedonia subscale of the BDI-II, is associated with suicidal ideation and that loss of interest is the most predictive factor. The authors suggest taking into account the different types of anhedonia when examining suicidal risk.

The second study, by the same team ⁴² used a sample of 1122 undergraduate students and examined the relationship between recent anhedonia change, suicidal ideation and suicide attempt. Winer et al. ⁴², used a total of three scales: the Specific Loss of Interest and Pleasure Scale (SLIPS, 11) that rates changes in the ability to take interest or pleasure in social experiences, the Center of Epidemiological Studies Depression Scale (CES-D), and the Suicidal Behaviors Questionnaire-Revised (SBQ-R). The Specific Loss of Interest Scale (SLIPS) was primarily designed to measure levels of interest over time (2 week period) ⁴³. Each of the 23-items has a 3-point scale, with higher scores denoting increasing levels of anhedonia.

The Specific Loss of Interest and Pleasure Scale (SLIPS) rates both the anticipatory and consummatory components of anhedonia as accurately as the anhedonia subscale from the BDI-II ⁴⁴. In a sample of 182 undergraduate students, one study reported significant correlations between the anticipatory or consummatory subscales of the Temporal Experience Pleasure Scale (TEPS) and the Specific Loss of Interest and Pleasure Scale (SLIPS) or the anhedonia subscale of the BDI-II ⁴⁴. Another study in various samples or healthy or psychiatric subjects reported significant correlations between the different items of the anhedonia subscale of BDI and the anticipatory or consummatory subscales of the Temporal Experience Pleasure Scale (TEPS) ³⁷.

Thus, changes in consummatory and anticipatory anhedonia and particularly in its social component were associated with suicidal ideation even when depressive symptoms were controlled for, although the association with suicide attempts was not significant.

Primary vs. secondary reward

The experience of pleasure can pertain to many stimuli that are instinctual (e.g. food, sex) versus non-instinctual (e.g. photography, reading). It could be argued that food and sex represent “primary” rewards (inherent rewards), whereas photography or money are secondary rewards (no inherent reward in itself and for which reward value must be learned). This distinction of “reward type” may complicate anhedonia research in two ways. First, neurobiological response to a primary reward may overlap with secondary reward, but may also have independent actions ⁴⁵. In a meta-analysis of 87 studies to determine the overlapping and distinct brain areas activated in response to monetary, erotic and food rewards, there were some differences in activation within a common network, which included the ventromedial prefrontal cortex, ventral striatum, amygdala, anterior insula and mediodorsal thalamus ⁴⁵. Notably, a study evaluating fluid and monetary incentives demonstrated that fluids were not as susceptible to contextual framing as secondary reward, and were more related to the experience of satiety or temperature ⁴⁶, which also may affect distinctions in neural activation. In particular, the primary rewards (food and erotic) resulted in activation of the anterior insula and amygdala (in the case of erotic reward), while the monetary secondary reward activated the orbitofrontal cortex. Furthermore, the authors suggest that even within the neocortex there may be a difference in how primary and secondary rewards are encoded. Accordingly, the more phylogenetically recent anterior portion of the OFC was more likely to respond to monetary reward. While the same group previously demonstrated that the posterior OFC is more activated in response to primary stimuli (e.g. erotic) ⁴⁷, this requires replication due to some inconsistencies in findings ⁴⁵. In contrast to the view of distinct activity with reward type, in a meta-analysis of 206 studies, Bartra and colleagues ⁴⁸ reported that both primary and secondary rewards activated the same brain regions including the striatum and ventromedial prefrontal cortex. Based on these findings, the authors suggest that assertions of domain-based differences in functional activity should be interpreted with caution.

Second, the distinction of incentive type limits the translation from preclinical to clinical studies, considering most preclinical work uses primary reward as incentive while most human studies employ secondary rewards. Importantly, investigation of primary reward provides a more direct comparison with animal studies. The following sections will expand on this idea through a review of the preclinical and clinical methods that have been developed to measure anhedonia and will also evaluate their generalizability and ability to measure the different facets of anhedonia. Indeed, one of the ultimate difficulties in measuring anhedonia lies in devising measures that tap into the objective or subjective nature of this construct.

Anhedonia causes

Anhedonia can arise from impairments in various facets of reward processing, including desire for reward, anticipation of reward, effort to attain reward, consummatory pleasure, as well as cognitive aspects of learning stimulus-reward associations ⁴⁹. Evidence suggests that there are specific neuroanatomical areas that underlie various facets of reward processing, including the prefrontal cortex (orbitofrontal cortex, ventromedial prefrontal cortex and anterior cingulate cortex), dorsal striatum (caudate and putamen), nucleus accumbens and amygdala. While dopamine has been the main neurotransmitter investigated in relation to reward, there is also mounting evidence that systems other than dopamine are critically involved in the reward process. Specifically, opioids, glutamate, gamma-aminobutyric acid (GABA) and serotonin also play a significant role. Opioids and GABA, for example, may be particularly important in the experience of consummatory pleasure ⁵⁰, while serotonin may be more associated with increased impulsivity and preference for immediate reward ⁵¹.

A significant body of literature suggests that inflammation or excessive immune activity, may underlie anhedonia across disorders ⁵². During acute inflammatory events, such as a cold, circulating inflammatory mediators produce “sickness behaviors” such as reduced activity, which serve the adaptive function of conserving energy and speeding healing ⁵³. However, maladaptive chronic low-grade inflammation appears to be present in many psychiatric disorders, and has been implicated in symptoms of anhedonia seen in depression, schizophrenia, and cancer-related fatigue, among other conditions ⁵⁴.

Anhedonia symptoms

Anhedonia is listed in the American Psychiatric Association, 2013, DSM-5 ⁵⁵ among the main schizophrenia negative symptoms, and it is defined as “the decreased ability to experience pleasure from positive stimuli or a degradation in the recollection of pleasure previously experienced.” Similar concepts—loss of interest or pleasure, not feeling any enjoyment in activities that were previously considered pleasurable—are also reported among the main symptoms and criteria for the diagnosis of major depressive disorder ⁵⁵. These symptoms are often associated with “social withdrawal.” The condition of anhedonia, that is, in its stricter connotation, the loss of feeling pleasure, is the disruption of just one facet in a complex reward-processing phenomenon that encompasses pleasure expectation, reward evaluation, determination of the effort necessary to obtain it, and planning and deciding the appropriate strategy to repeat the pleasurable experience. A deficit in any of these aspects in the reward process may result in behaviors that could be interpreted as “anhedonia.” For instance, the expression “a degradation in the recollection of pleasure previously experienced” refers to pleasure-triggered cognitive processes codified in brain areas and by mechanisms very likely different from those underpinning pleasure perception ⁵⁶, and this is true either for the recollection of a previous pleasurable experience or for its degradation. Thus, although several authors strongly sustain that the definition of anhedonia should be restricted to a well-defined neurobiological construct ⁵⁶, the term is often used both in the clinical evaluation of patients and in basic science experimental contexts in a broader connotation.

Anhedonia test

Anhedonia measurement in depressed humans utilizes direct symptom scales or behavioral tasks ⁵⁷. While scale methods provide direct evidence of patients’ experience, combining behavioral methods with neuroimaging offers an opportunity to disentangle different components of reward processing and identify neurobiological underpinnings associated with such abnormalities.

The four main validated self-report measures of anhedonia used in clinical research are the Snaith-Hamilton Pleasure Scale (SHAPS) ⁵⁸, the Fawcett-Clark Pleasure Capacity Scale (FCPS) ⁵⁹, the Revised Chapman Physical Anhedonia Scale (CPAS) and the Chapman Social Anhedonia Scale (CSAS) ⁶⁰ (Table 1). Ideally, a scale quantifying anhedonia in the context of major depressive disorder should be able to measure different aspects of anhedonia, detect state versus trait differences, and take into account varying cultural beliefs and preferences (generalizability). Although all of these scales have been validated in clinical populations, they differ in their ability to meet these criteria ⁵⁷.

The Snaith-Hamilton Pleasure Scale (SHAPS) ⁵⁸ remains the gold standard for measuring anhedonia in depression ⁵⁷. It is recommended that any scale should be validated in the population of interest prior to use. While the Revised Chapman Physical Anhedonia Scale (CPAS) and Chapman Social Anhedonia Scale (CSAS) have been used in to assess anhedonia in studies of depression, only the Snaith-Hamilton Pleasure Scale (SHAPS) ⁵⁸, Fawcett-Clark Pleasure Capacity Scale (FCPS) ⁵⁹ and Dimensional Anhedonia Rating Scale (DARS) ⁶¹ have undergone empirical scale validation procedures in major depressive disorder samples. Although the SHAPS only measures consummatory pleasure, it does so across several domains and with limited cultural biases. Considering consummatory reward is not consistently impaired in depression, the SHAPS may be useful to identify subgroups within major depressive disorder or test specific effects of treatment, but may not have the sensitivity to be utilized as a predictor of treatment response. Further study is needed to determine whether deficits in reward responding are dependent on reward type (e.g. social, food, physical), for which the Dimensional Anhedonia Rating Scale (DARS) ⁶¹ may be able to tease apart any potential differences given its component structure is based on reward type. Most importantly, in light of emerging evidence indicating that different facets of reward processing are subserved by partially dissociable neurobiological systems (Der-Avakian & Markou, 2012), it will be imperative for future scale development to evaluate desire, motivation, effort, and consummatory pleasure across different domains of anhedonia, as well as measuring the stability of the construct.

Table 1. First generation scales to measure anhedonia

In the last 8 years there has been a resurgence in refining anhedonia scales with at least 4 new published self-report questionnaires (Table 2), which attempt to take into account different facets of reward function instead of only consummatory pleasure. All of these scales take approximately 5-10 minutes to complete.

Table 2. Second generation scales to measure anhedonia

Anhedonia treatment

No effective treatments for anhedonia have been found to date. Ketamine, recently the focus of research ⁶⁶ as a rapid-acting antidepressant that can ease symptoms within hours instead of weeks, is now being studied as a fast-acting mood-lifter to treat bipolar patients. To test their theory, the researchers infused Ketamine or a placebo into 36 patients in the depressive phase of bipolar disorder ⁶⁷. They then detected any mood changes using rating scales for anhedonia and depression. By isolating scores on anhedonia from scores on other depression symptoms, the researchers discovered that ketamine was triggering a strong anti-anhedonia effect sooner — and independent of — the other effects, they report in the study, which was published in the journal Translational Psychiatry. Levels of anhedonia plummeted within 40 minutes in patients who received ketamine, compared with those who received the placebo, according to the researchers, who add the effect was still detectable in some patients two weeks later.

Other depressive symptoms improved within two hours, the researchers noted. The anti-anhedonic effect remained significant even in the absence of other antidepressant effects, suggesting a unique role for the drug.

Next, the researchers scanned the brains of a subset of the ketamine-infused patients, using positron emission tomography (PET), which shows what parts of the brain are active by tracing the destinations of radioactively-tagged glucose — the brain’s fuel.

The scans showed that ketamine jump-started activity not in the middle brain area they had expected, but rather in the dorsal (upper) anterior cingulate cortex, near the front middle of the brain, and putamen, deep in the right hemisphere.

Boosted activity in these areas may reflect increased motivation towards or ability to anticipate pleasurable experiences, according to the researchers.

Depressed patients typically experience problems imagining positive, rewarding experiences, which would be consistent with impaired functioning of this dorsal anterior cingulate cortex circuitry, they said.

However, confirmation of these findings must await results of a similar NIMH (National Institute of Mental Health) ketamine trial nearing completion in patients with unipolar major depression, the researchers noted.

Other evidence suggests that ketamine’s action in this circuitry is mediated by its effects on the brain’s major excitatory neurotransmitter, glutamate, as well as downstream effects on a key reward-related chemical messenger, dopamine.

The findings add to mounting evidence in support of the antidepressant efficacy of targeting this neurochemical pathway, according to the researchers. Ongoing research is exploring, for example, potentially more practical delivery methods for ketamine and related experimental antidepressants, such as a nasal spray, they noted.

Recent 2016 meta analysis ⁶⁸, which drew data from several clinical trials of ketamine in individuals with treatment-resistant major depressive disorder or bipolar disorder, found an association between reductions in suicidal thoughts and anhedonia that occurred independently of depressive symptoms. The authors also found that anhedonia, as measured by the Snaith-Hamilton Pleasure Scale (SHAPS), was associated with suicidal thoughts independent of depressive symptoms both before and after ketamine administration ⁶⁸. One day post-ketamine administration, improvements on the SHAPS accounted for an additional 13% of the variance in suicidal thought reduction, beyond the influence of depressive symptoms. The Beck Depression Inventory (BDI) anhedonia subscale was not significantly associated with suicidal thoughts after adjusting for depressive symptoms. They concluded that suicidal thoughts may be related to symptoms of anhedonia independent of other depressive symptoms. These results have implications for the potential mechanisms of action of ketamine on suicidal thoughts ⁶⁸.

1. American Psychiatric Association, DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. American Psychiatric Association: Arlington, VA; 2013.[↩][↩][↩]
2. Klein D. Depression and anhedonia. In: Clark C, Fawcett J, eds. Anhedonia and Affect Deficit States. New York, NY: PMA Publishing; 1984[↩]
3. Diagnostic differences in social anhedonia: a longitudinal study of schizophrenia and major depressive disorder. Blanchard JJ, Horan WP, Brown SA. J Abnorm Psychol. 2001 Aug; 110(3):363-71.[↩]
4. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Volkow ND, Fowler JS, Wang GJ, Goldstein RZ. Neurobiol Learn Mem. 2002 Nov; 78(3):610-24.[↩]
5. Physical anhedonia in Parkinson’s disease. Isella V, Iurlaro S, Piolti R, Ferrarese C, Frattola L, Appollonio I, Melzi P, Grimaldi M. J Neurol Neurosurg Psychiatry. 2003 Sep; 74(9):1308-11.[↩]
6. Sensitivity to the rewarding effects of food and exercise in the eating disorders. Davis C, Woodside DB. Compr Psychiatry. 2002 May-Jun; 43(3):189-94.[↩]
7. Are nonpharmacological induced rewards related to anhedonia? A study among skydivers. Franken IH, Zijlstra C, Muris P. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Mar; 30(2):297-300.[↩]
8. Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. McMakin DL, Olino TM, Porta G, Dietz LJ, Emslie G, Clarke G, Wagner KD, Asarnow JR, Ryan ND, Birmaher B, Shamseddeen W, Mayes T, Kennard B, Spirito A, Keller M, Lynch FL, Dickerson JF, Brent DA. J Am Acad Child Adolesc Psychiatry. 2012 Apr; 51(4):404-11.[↩][↩]
9. Nutt D, Demyttenaere K, Janka Z, Aarre T, Bourin M, Canonico PL, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol. 2007;21:461–471.[↩]
10. McCabe C, Mishor Z, Cowen PJ, Harmer CJ. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment. Biol Psychiatry. 2010;67:439–445[↩]
11. Hindmarch I. The behavioural toxicity of antidepressants: effects on cognition and sexual function. Int Clin Psychopharmacol. 1998;13 (Suppl 6:S5–S8.[↩]
12. Landen M, Hogberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry. 2005;66:100–106[↩]
13. Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D, et al. Time-related predictors of suicide in major affective disorder. Am J Psychiatry. 1990;147:1189–1194.[↩]
14. Leung WW, Couture SM, Blanchard JJ, Lin S, Llerena K. Is social anhedonia related to emotional responsivity and expressivity? A laboratory study in women. Schizophr Res. 2010;124(1-3):66-73. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962705/[↩]
15. Zhang B, Lin P, Shi H, et al. Mapping anhedonia-specific dysfunction in a transdiagnostic approach: an ALE meta-analysis. Brain Imaging Behav. 2015;10(3):920-39. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4838562/[↩][↩]
16. The neurobiology of anhedonia and other reward-related deficits. Der-Avakian A, Markou A. Trends Neurosci. 2012 Jan; 35(1):68-77.[↩][↩]
17. Reconsidering anhedonia in depression: lessons from translational neuroscience. Treadway MT, Zald DH. Neurosci Biobehav Rev. 2011 Jan; 35(3):537-55.[↩]
18. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Whitton AE, Treadway MT, Pizzagalli DA. Curr Opin Psychiatry. 2015 Jan; 28(1):7-12.[↩]
19. Anhedonia and the brain reward circuitry in depression. Curr Behav Neurosci Rep. Author manuscript; available in PMC 2016 Sep 1. doi: 10.1007/s40473-015-0044-3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4626008/[↩]
20. Reduced reward learning predicts outcome in major depressive disorder. Vrieze E, Pizzagalli DA, Demyttenaere K, Hompes T, Sienaert P, de Boer P, Schmidt M, Claes S. Biol Psychiatry. 2013 Apr 1; 73(7):639-45.[↩]
21. Dimensions in major depressive disorder and their relevance for treatment outcome. Vrieze E, Demyttenaere K, Bruffaerts R, Hermans D, Pizzagalli DA, Sienaert P, Hompes T, de Boer P, Schmidt M, Claes S. J Affect Disord. 2014 Feb; 155():35-41.[↩]
22. The neural correlates of anhedonia in major depressive disorder. Keedwell PA, Andrew C, Williams SC, Brammer MJ, Phillips ML. Biol Psychiatry. 2005 Dec 1; 58(11):843-53.[↩]
23. Common and Dissociable Dysfunction of the Reward System in Bipolar and Unipolar Depression. Satterthwaite TD, Kable JW, Vandekar L, Katchmar N, Bassett DS, Baldassano CF, Ruparel K, Elliott MA, Sheline YI, Gur RC, Gur RE, Davatzikos C, Leibenluft E, Thase ME, Wolf DH. Neuropsychopharmacology. 2015 Aug; 40(9):2258-68.[↩]
24. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Bewernick BH, Hurlemann R, Matusch A, Kayser S, Grubert C, Hadrysiewicz B, Axmacher N, Lemke M, Cooper-Mahkorn D, Cohen MX, Brockmann H, Lenartz D, Sturm V, Schlaepfer TE. Biol Psychiatry. 2010 Jan 15; 67(2):110-6.[↩]
25. Pizzagalli D. A., Jahn A. L., & O’Shea J. P. (2005). Toward an objective characterization of an anhedonic phenotype: A signal-detection approach. Biological Psychiatry, 57(4), 319–327.[↩]
26. Cuthbert B. N. (2014). The RDoC framework: Facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry: Official Journal of the World Psychiatric Association (WPA), 13(1), 28–35.[↩]
27. Afzali M. H., Sunderland M., Teesson M., Carragher N., Mills K., & Slade T. (2017). A network approach to the comorbidity between posttraumatic stress disorder and major depressive disorder: The role of overlapping symptoms. Journal of Affective Disorders, 208, 490–12.[↩]
28. Der-Avakian A., & Markou A. (2012). The neurobiology of anhedonia and other reward-related deficits. Trends in Neurosciences, 35(1), 68–77[↩]
29. Nawijn L., van Zuiden M., Frijling J. L., Koch S. B., Veltman D. J., & Olff M. (2015). Reward functioning in PTSD: A systematic review exploring the mechanisms underlying anhedonia. Neuroscience & Biobehavioral Reviews, 51, 189–204.[↩]
30. Eskelund K, Karstoft KI, Andersen SB. Anhedonia and emotional numbing in treatment-seeking veterans: behavioural and electrophysiological responses to reward. Eur J Psychotraumatol. 2018;9(1):1446616. Published 2018 Mar 15. doi:10.1080/20008198.2018.1446616 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912443/[↩][↩]
31. Armour C., Tsai J., Durham T. A., Charak R., Biehn T. L., Elhai J. D., & Pietrzak R. H. (2015). Dimensional structure of DSM-5 posttraumatic stress symptoms: Support for a hybrid Anhedonia and externalizing behaviors model. Journal of Psychiatric Research, 61, 106–113.[↩][↩]
32. Pietrzak R. H., Tsai J., Armour C., Mota N., Harpaz-Rotem I., & Southwick S. M. (2015). Functional significance of a novel 7-factor model of DSM-5 PTSD symptoms: Results from the National Health and Resilience in Veterans Study. Journal of Affective Disorders, 174, 522–526.[↩]
33. Garfield JBB, Lubman DI, Yücel M. Anhedonia in substance use disorders: A systematic review of its nature, course and clinical correlates. Aust N Z J Psychiatry. 2013;48: 36–51. 10.1177/0004867413508455[↩][↩]
34. Leventhal AM, Piper ME, Japuntich SJ, Baker TB, Cook JW. Anhedonia, depressed mood, and smoking cessation outcome. J Consult Clin Psychol. 2014;82: 122–129. 10.1037/a0035046[↩]
35. Lubman DI, Yücel M, Kettle JWL, Scaffidi A, MacKenzie T, Simmons JG, et al. Responsiveness to drug cues and natural rewards in opiate addiction: Associations with later Heroin use. Arch Gen Psychiatry. American Medical Assn: US; 2009;66: 205–213. 10.1001/archgenpsychiatry.2008.522[↩]
36. Yaseen ZS, Galynker II, Briggs J, Freed RD, Gabbay V.Functional domains as correlates of suicidality among psychiatric inpatients.J Affect Disord. 2016;203:77–83 doi: 10.1016/j.jad.2016.05.066[↩]
37. Loas G. Anhedonia in suicide behavior In Anhedonia : a comprehensive handbook. New York: Springer, 2014.[↩][↩]
38. Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D, et al. Time-related predictors of suicide in major affective disorder.Am J Psychiatry. 1990; 147(9):1189–94. doi: 10.1176/ajp.147.9.1189[↩]
39. Loas G. Anhedonia and suicide: a 6.5-yr. follow-up study of patients hospitalized for a suicide attempt.Psychol Rep. 2007; 100(1):183–90. doi: 10.2466/pr0.100.1.183-190[↩]
40. Gard D.E., Germans Gard M, Kring A.M, John O.P. Anticipatory and consummatory components of the experience of pleasure: a scale development study. Journal of Research in Personality.2006; 40 (6): 1086–1102[↩]
41. Winer ES, Nadorff MR, Ellis TE, Allen JG, Herrera S, Salem T.Anhedonia predicts suicidal ideation in a large psychiatric inpatient sample.Psychiatry Res. 2014; 218(1–2):124–8 doi: 10.1016/j.psychres.2014.04.016[↩][↩][↩]
42. Winer ES, Drapeau CW, Veilleux JC, Nadorff MR.The Association between Anhedonia, Suicidal Ideation, and Suicide Attempts in a Large Student Sample. Arch Suicide Res. 2016;20(2):265–72. doi: 10.1080/13811118.2015.1025119[↩][↩]
43. Winer ES, Veilleux JC, Ginger EJ. Development and validation of the Specific Loss of Interest and Pleasure Scale (SLIPS) J Affect Disord. 2014:152–154. 193–201.[↩]
44. Winer ES, Veilleux JC, Ginger EJ.Development and validation of the Specific Loss of Interest and Pleasure Scale (SLIPS).J Affect Disord. 2014;152–154:193–201. doi: 10.1016/j.jad.2013.09.010[↩][↩]
45. Processing of primary and secondary rewards: a quantitative meta-analysis and review of human functional neuroimaging studies. Sescousse G, Caldú X, Segura B, Dreher JC. Neurosci Biobehav Rev. 2013 May; 37(4):681-96.[↩][↩][↩]
46. Time discounting for primary rewards. McClure SM, Ericson KM, Laibson DI, Loewenstein G, Cohen JD. J Neurosci. 2007 May 23; 27(21):5796-804.[↩]
47. The architecture of reward value coding in the human orbitofrontal cortex. Sescousse G, Redouté J, Dreher JC. J Neurosci. 2010 Sep 29; 30(39):13095-104.[↩]
48. Bartra O, McGuire JT, Kable JW. The valuation system: a coordinate-based meta-analysis of BOLD fMRI experiments examining neural correlates of subjective value. Neuroimage. 2013;76:412-27. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756836/[↩]
49. Rizvi SJ, Pizzagalli DA, Sproule BA, Kennedy SH. Assessing anhedonia in depression: Potentials and pitfalls. Neurosci Biobehav Rev. 2016;65:21-35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856554/[↩]
50. Activation of VTA GABA neurons disrupts reward consumption. van Zessen R, Phillips JL, Budygin EA, Stuber GD. Neuron. 2012 Mar 22; 73(6):1184-94.[↩]
51. Low-serotonin levels increase delayed reward discounting in humans. Schweighofer N, Bertin M, Shishida K, Okamoto Y, Tanaka SC, Yamawaki S, Doya K. J Neurosci. 2008 Apr 23; 28(17):4528-32.[↩]
52. Felger JC, Lotrich FE. Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications. Neuroscience. 2013;246: 199–229. 10.1016/j.neuroscience.2013.04.060[↩]
53. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. Nature Publishing Group; 2008;9: 46–56. 10.1038/nrn2297[↩]
54. Réus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience. 2015/05/20. 2015;300: 141–154. 10.1016/j.neuroscience.2015.05.018[↩]
55. American Psychiatric Association (2013)Diagnostic and statistical manual of mental disorders 5th Edition (DSM-5). Washington, DC: APA.[↩][↩]
56. Der-Avakian A, Markou A.(2012)The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 35:68–77.[↩][↩]
57. Assessing anhedonia in depression: Potentials and pitfalls. Neurosci Biobehav Rev. Author manuscript; available in PMC 2017 Jun 1. doi: 10.1016/j.neubiorev.2016.03.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856554/[↩][↩][↩][↩][↩]
58. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. Br J Psychiatry. 1995 Jul; 167(1):99-103.[↩][↩][↩][↩]
59. Assessing anhedonia in psychiatric patients. Fawcett J, Clark DC, Scheftner WA, Gibbons RD. Arch Gen Psychiatry. 1983 Jan; 40(1):79-84.[↩][↩][↩]
60. Scales for physical and social anhedonia. Chapman LJ, Chapman JP, Raulin ML. J Abnorm Psychol. 1976 Aug; 85(4):374-82.[↩][↩][↩]
61. Rizvi SJ, Quilty LC, Sproule BA, Cyriac A, Michael Bagby R, Kennedy SH. Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression. Psychiatry Res. 2015;229:109–19[↩][↩][↩]
62. Gard DE, Germans Gard M, Kring AM, John OP. Anticipatory and consummatory components of the experience of pleasure: A scale development study. Journal of Research in Personality. 2006;40:1086–1102[↩]
63. Llerena K, Park SG, McCarthy JM, Couture SM, Bennett ME, Blanchard JJ. The Motivation and Pleasure Scale-Self-Report (MAP-SR): reliability and validity of a self-report measure of negative symptoms. Compr Psychiatry. 2013;54:568–74.[↩]
64. Winer ES, Veilleux JC, Ginger EJ. Development and validation of the Specific Loss of Interest and Pleasure Scale (SLIPS) J Affect Disord. 2014:152–154. 193–201[↩]
65. Further validation of the ACIPS as a measure of social hedonic response. Gooding DC, Pflum MJ. Psychiatry Res. 2014 Mar 30; 215(3):771-7[↩]
66. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4(10):e469. Published 2014 Oct 14. doi:10.1038/tp.2014.105 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350513/[↩]
67. Lally N., Nugent A. C., Luckenbaugh D. A., Ameli R., Roiser J. P., & Zarate C. A. (2014). Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Translational Psychiatry.[↩]
68. Ballard ED, Wills K, Lally N, et al. Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials. J Affect Disord. 2017;218:195-200. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515296/[↩][↩][↩]